Disproven
Dirucotide: slow disability worsening in secondary progressive MS
secondary progressive MS · Cell therapies and tolerisation
Placebo-controlled phase 3 trials missed their main goal, and none succeeded. This applies to this patient group only.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 1106
Deciding trials (phase 3): 0 met, 2 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2007 · Placebo-controlled · MSFT-NCT00468611
Phase 2/3 · 2004 · Placebo-controlled · MSFT-NCT00869726
Results There were no significant differences between treatment groups in either the primary or secondary endpoints.
Read by software from the paper's abstract
Other linked trials: 1
These linked trials do not set the status.
- A double-blind placebo-controlled multicenter study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS)Result in a paper, not read yet
Phase Not recorded · 2004 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-30Status changed from Results pending to Disproven
- 2026-10-28Trials: 2 → 3
- 2026-10-28Trials: 3 → 2
- 2026-10-27First listed as Results pending
Related hypotheses
- Cell therapies and tolerisation: protect nerve tissue in secondary progressive MS
- Cell therapies and tolerisation: repair myelin in secondary progressive MS
- Cell therapies and tolerisation: reset the immune system for lasting remission in secondary progressive MS
- Cell therapies and tolerisation: slow disability worsening in secondary progressive MS
- Evruleucel: slow disability worsening in secondary progressive MS
- Rildinadstrocel: slow disability worsening in secondary progressive MS
- Cell therapies and tolerisation: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error